Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've stopped semaglutide and want to begin again, the practical answer is this: you'll almost certainly need to go back to a lower dose, work through the titration schedule, and have your situation reviewed by a prescriber before resuming. That's true whether your break was two weeks or six months. Semaglutide is a prescription-only medicine, so restarting always involves a clinical assessment — not just picking up where you left off.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The length of your break shapes almost everything about how you restart. It's a question our prescribers hear most weeks, and the answer isn't one-size-fits-all.
If you stopped for less than two weeks, you may be able to resume at the same dose you left, but only if your prescriber agrees after reviewing your current situation. Two to four weeks off is a grey area: some patients tolerate continuing at the previous dose, others find the gastrointestinal side effects have largely reset. Beyond four weeks, clinical guidance is consistent: treat it as a fresh start from a lower dose.
The NHS semaglutide medicines page is clear that missed doses and breaks should be discussed with a healthcare professional rather than managed by the patient alone. That's not a formality, the dose you were on before your break may no longer reflect your current tolerance or your current health picture. You can find more detail on very short breaks at our two-week gap guide and on slightly longer pauses in the three-week break resource.
Restarting semaglutide (like starting it for the first time) requires a prescriber to assess you. Your weight may have changed. A new health condition may have developed. The dose that was working well before might not be the right dose now.
A prescriber review covers your current BMI, any changes to your medical history, what medications you're taking, and which strength is appropriate to restart on. At nume, that review is carried out the same day by a GPhC-registered prescriber, not an automated system. If you're coming back to treatment after some time away, it's worth being honest about what changed during your break, whether that's regained weight, a new diagnosis, or simply the circumstances that caused you to stop.
If you were previously on Wegovy through another provider, the semaglutide overview explains what the UK prescribing process involves, and the Wegovy pillar page covers current eligibility in full. You can also explore treatment options at the consultation hub.
This is the step people most often want to skip. If you were on 1.7mg or 2.4mg before your break, going straight back to that dose after a significant gap can trigger a sharp return of nausea, vomiting, and other gastrointestinal effects that your body had previously adjusted to.
The standard approach is to restart at a lower dose and work back up through the titration schedule, typically in four-week steps. The NHS England guidance on weight-management injections reinforces this principle: titration exists to help your system adapt, and restarting after a break is functionally similar to starting for the first time in terms of tolerance.
Common side effects during retitration include nausea, loose stools, and fatigue, especially in the first week or two at each new dose. These generally ease as your body readjusts. What to expect at each step is set out in the Patient Information Leaflet that comes with your medicine, your prescriber is the right person to advise on timings specific to your situation. For a fuller picture of what restarting after roughly a month looks like in practice, the one-month gap page goes into more detail, as does the broader restarting after a month resource.
Weight returning after stopping semaglutide is not a sign of failure. It reflects the way the medicine works: appetite suppression reduces when the drug leaves your system, and eating patterns can shift back. This is one of the most common concerns patients raise when they're considering restarting Wegovy after a break.
The clinical trial evidence backs this up. STEP 1, published in the New England Journal of Medicine, showed that participants who stopped semaglutide regained a substantial portion of lost weight within a year, while those who continued maintained their results. This matters when you're restarting: your prescriber will reassess your current weight and health status rather than relying on figures from before you stopped.
If you'd like to read about the broader evidence before your consultation, the semaglutide restart overview and the weight-loss treatments page both give useful context. When you're ready to speak to a prescriber, check your eligibility and start your free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.